BioSpace News Archive

Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed.

Pneuma Systems Corporation (Pneuma), an emerging leader in the infusion therapy industry, today announced a new partnership with Apex Ridge Consulting (www.apexridge.com).

Fresenius Kabi announced today the introduction of a three-year plan to add GS1 Data Matrix barcodes to its pharmaceutical portfolio of vials, syringes, IV solutions and parenteral nutrition products at the unit of use.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2022.

Cocrystal Pharma, Inc. announces it has engaged hVIVO to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral candidate CC- 42344.

Impel Pharmaceuticals Inc. today announced it will host a live webcast on Monday, August 15, 2022, at 8:30 a.m. ET to report its second quarter 2022 financial results and provide a business update.

Gain Therapeutics, Inc. today announced its financial results for the second quarter ended June 30, 2022, and highlighted recent corporate progress.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the second quarter ended June 30, 2022, before the financial markets open on Monday, August 15, 2022.

Spectral Medical Inc. today announced that Dialco, along with its distribution partner, Marathon Medical Corporation, have been awarded a five year Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide SAMI CRRT (chronic renal replacement therapy) dialysis devices and associated maintenance services to the United States Department of Veterans Affairs’ (VA) national healthcare system.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC (“DXOCRO”) to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States.